JAG1 and pulmonary arterial hypertension: Furthermore, treatment of animals with the anti-NOTCH3 antibody did not lead to local or systemic toxicity, suggesting that blocking JAG1-dependent activation of NOTCH3 signalling could be a promising therapeutic strategy for treating patients with PAH.